Cited by 516Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments

The DOI matches its Crossref record.

Alzheimer Neuropathologic Alterations in Aged Cognitively Normal Subjects

Davis, D G, Schmitt, F A, Wekstein, D R, Markesbery, W R·1999·Journal of Neuropathology and Experimental Neurology

DOI 10.1097/00005072-199904000-00008

Open this paper in CoChat — free account

Abstract

The histopathologic changes distinguishing early Alzheimer disease (AD) from normal or pathologic aging are not clearly defined. This report describes the autopsy findings of 59 elderly, well-educated, volunteers. They were examined longitudinally with mental status testing, some for up to 8 years, as part of our normal aging study. This study reveals that (1) the brains of many subjects who did not show cognitive impairment on neuropsychologic testing contain abundant senile plaques (SP) and/or neurofibrillary tangles (NFT); (2) 29 subjects met Khachaturian criteria for AD, 15 met CERAD and 7 met National Institute on Aging-Reagan Institute guidelines; (3) Braak and Braak staging method included 9 in stage IV subjects, 4 in stage V, and 1 in stage VI; (4) there was a progression of NFT from entorhinal cortex to hippocampus and amygdala as a function of age; (5) 2 subjects met criteria for a diagnosis of dementia with Lewy bodies but were not demented; (6) cerebral amyloid angiopathy was present in leptomeningeal vessels in 75% of subjects and in parenchymal vessels in 62% of subjects; (7) only 10 of 59 subjects (17%) had no or few degenerative brain changes. Our study demonstrates that the brains of a large percentage of cognitively normal, relatively well-educated individuals contain numerous degenerative changes and only a small percentage are relatively free of these changes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/00005072-199904000-00008

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The publisher hasn’t deposited this paper’s reference list.

Research works printed but not linked: 37

[1]1. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the ncuropathologic assessment of Alzheimer's disease. Neurology1991;41:479-86
[2]2. The National Institute on Aging and Reagan Institute Working Group. Consensus recommendations for the postmortem diagnosis of Alzheimer's discase. Neurobiol Aging 1997;18:S1–S2
[3]3. Berg L, McKeel D, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol 1993;50:349–58
[4]4. Berg L, McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326–35
[5]5. Bouras C. Hof PR, Giannakopoulos P. Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex 1994;4:138–50
[6]6. Crystal HA, Dickson DW, Sliwinski MJ, et al. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol 1993;34:566-73
[7]7. Giannakopoulos P, Hof PR, Mottier S, Michel JP, Bouras C. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: Retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol 1994;87:456–68
[10]10. Morris JC. Storandt M. MeKeel DW, et al. Cerebral amyloid deposition and difuse plaques in "normal" aging: evidence for presymptomatie and very mild Alzheimer's disease. Neurology 1996; 46:707-19
[11]11. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson P, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457–59
[12]12. Haroutunian V, Perl DP, Purohit DP, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer discase. Arch Neurol 1998;55:1185–91
[13]13. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC. Increased incidence of neurofibrillary tangles (NFT) in nondemented individuals with hypertension, J Neurol Sci 1995;131: 162-69
[14]14. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzleiner's disease, Neurobiol Aging 1990;11:601–7
[15]15. Sparks DL, Liu H, Scheff SW, Coyne CM, Hunsaker JC. Temporal sequence of plaque formation in cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol 1993;52:135–42
[16]16. Soneira CF, Scott TM. Severe cardiovascular disease and Alzheimer's disease. Clin Anat 1996;9:118–27
[17]17. Hulette CM, Welsh-Bohmer KA, Murray MG, ct al. Neuropathological and neuropsychological changes in "normal" aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998;57:1 168–74
[18]18. Kazec AM, Eskin TA, Lapham LW, Gabriel KR, McDanicl KD, Hamill RW. Clinicopathologic correlates in Alzheimer's discase: Assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis Assoc Disord 1993;7:152–64
[20]20. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–59
[27]27. Itoh Y, Yamada M, Yoshida R, et al. Dementia characterized by abundant neurofibrillary tangles and scarce senile plaques: A quantitative pathological study. Eur Neurol 1996;36:94–97
[28]28. Ikeda K, Akiyama H, Ari T, et al. A subset of senile dementia with high incidence of the apolipoprotcin Ee2 allele. Ann Neurol 1997; 41:693-95
[29]29. Boncher C, Jellinger KA. Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: A rare subtype in very old subjects, Acta Neuropathol 1994;88:565–70
[30]30. Ulrich J. Spillantini MG, Gocdert M, Dukas L, Stahelin HB. Abundant neurofbrillary tangles without senile plaques in a subset of patients with senile dementia. Neurodegencration 1992;1:257–64
[31]31. Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:44–52
[33]33. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA. Markesbery WR. Brain infarction and the clinical expression of Alzheimer Discase. JAMA 1997;277:813–17
[34]34. Nagy Z. Esri ME, Jobst KA, et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 1997;56:165-70
[35]35. Braak H, Braak E. Cortical and subeortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol Appl Neurobiol 1989;15:13–26
[36]36. Braak H. Braak E. Argyrophilic grains: Claracteristic pathology of the cerebral cortex in cases of adult onset deinentia without Alzheimer changes. Neurosci Lett 1987;76:124–27
[38]38. Davis DG. Ross GW, Petrovitch H. et al. Quantitation of argyrophilic grains in hippocampal CA-I of aged Japanese-American males. (Abstract) J Neuropathol Exp Neurol 1997;56:587
[21]21. Braak H, Braak E: Pathology of Alzheimer's discase, In: Calne DB, 40. Esiri MM, Wilcock GK. Cerebral amyloid angiopathy in dementia ed. Neurodegenerative diseases. Philadelphia: W.B. Saunders,1994: and old age. J Neurol Neurosurg Psychiatry 1986;49:1221–26 585-614
[22]22. Khachaturian ZS. Diagnosis of Alzheinier's disease. Areh Neurol 1985;42:1097–1105
[23]23. MeKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-24
[24]24. Morrison JH, Hof PR. Life and death of neurons in the aging brain. Science 1997;278:412–19
[25]25. Geddes JW, Snowdon DA, Soultanian NS, et al. Braak stages IIIIV of Alzheimer-related neuropathology are associated with dementia: Findings from the Nun study. (Abstract) J Neuropathol Exp Neurol 1996;55:617
[39]39. Tolnay M, Schwietert M, Monsch AU, Staehelin HB, Langui D, Probst A. Argyrophilic grain disease: Distribution of grains in patients with and without dementia. Acta Neuropathol 1997;94:353–58
[41]41. Masuda J, Tanaka K, Ueda K, Omae T. Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama Japan. Stroke 1988;19:205–10
[42]42. Wu E, Lipton RB, Dickson DW. Amyloid angiopathy in diffuse Lewy body discase. Neurology 1992;42:2131–35
[43]43. Yamada M, Tsukagoshi H, Otomo E, Hayakawa M. Cerebral amyloid angiopathy in the aged. J Neurol 1987;234:371–76
[44]44. Schofield P. Mayeux R. Alzhcimer's disease; Clinical features, diagnosis and epidemiology. In: Markesbery WR, ed. Neuropathology of dementing disorders. London: Edward Arnold;1998:89–105 Received November 9, 1998 Revision reccived January 19, 1999 Accepted January 21, 1999

Sorted by citations

Items 201–300 of 515

Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration
Blaylock, R. L. (2017) · Surgical Neurology International · doi:10.4103/sni.sni_441_16 · Cited by 67
“It could also depend on the strength of the person’s antioxidant network, detoxification systems, and mitochondrial health.[63]”
Background
F2-Isoprostanes as Biomarkers of Late-onset Alzheimer’s Disease
Montine, T. J., Quinn, J. F., Kaye, J. A., & Morrow, J. D. (2007) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-0044-1 · Cited by 65
“…demonstrated to be cognitively normal (Price et al. 1991; Arriagada et al. 1992; Berg et al. 1993; Crystal et al. 1993; Hulette et al. 1998; Davis et al. 1999; Haroutunian et al. 1999; Price and Morris 1999; Green et al. 2000; Schmitt et al. 2000; Xuereb et al. 2000; Morris and Price 2001;…”
Background
Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier
Osgood, D., Miller, M. C., Messier, A. A., Gonzalez, L., & Silverberg, G. D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.011 · Cited by 63
“, 2008), and the accumulation of Ab is felt to be central to AD pathogenesis (Hardy, 2006; Querfurth and LaFerla, 2010; Selkoe, 2000), it is of more than passing interest to understand the mechanisms involved in the expression alterations of the Ab transport receptors at the brain barriers that occur in the nondemente…”
Cerebral amyloid angiopathy in the elderly: vessel walls changes and relationship with dementia
Zekry, D., Duyckaerts, C. J., Belmin, J., Geoffre, C., Moulias, R., & Hauw, J. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0738-6 · Cited by 63
“However, they have also been found in so-called “cognitively normal aged persons” [ 5 , 11, 14, 17, 23, 35, 45].”
Designing a Brief Alzheimer Screen (BAS)
Mendiondo, M. S., Ashford, J. W., Kryscio, R. J., & Schmitt, F. A. (2003) · Journal of Alzheimer s Disease · doi:10.3233/jad-2003-5506 · Cited by 64
“…(Memory Clinic referrals), with 70 “non-demented” patients (no MCI or dementia diagnosis, MMSE and category ﬂuency recorded), and 658 control subjects from the BRAiNS study of elderly volunteers from the community who are evaluated each year and donate their brain for autopsy after death [11,47].”
Self-citation
Amyloid‐β in Alzheimer's disease: the horse or the cart? Pathogenic or protective?
Lee, H., Castellani, R. J., Zhu, X., Perry, G. L., & Smith, M. A. (2005) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2005.00429.x · Cited by 66
Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?
Jellinger, K. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0466-z · Cited by 60
“Diffuse and neuritic plaques and some amounts of tau-positive neuritic pathology in the limbic system relatively frequently occur in cognitively normal elderly [50,112,114,187-195].”
Background
Synapse Stability in the Precuneus Early in the Progression of Alzheimer's Disease
Scheff, S. W., PRICE, D. A., Schmitt, F. A., Roberts, K. N., Ikonomović, M. D., & Mufson, E. J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122353 · Cited by 60
“9 years; range 73 to 99 years; Table 1) who were participants in either the Rush Religious Orders Study (RROS), a longitudinal clinical-pathologic studies of aging and AD composed of older Catholic nuns, priests, and brothers [27–29], or the University of Kentucky Alzheimer’s Disease Center (UKADC) [30].”
Self-citation
Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Tonda‐Turo, C., Origlia, N., Mattu, C., Accorroni, A., & Chiono, V. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180221125759 · Cited by 61
Cerebrospinal fluid ratios with Aβ 42 predict preclinical brain β‐amyloid accumulation
Racine, A. M., Koscik, R. L., Nicholas, C. R. N., Clark, L. R., Okonkwo, O. C., Oh, J. M., Hillmer, A. T., Murali, D., Barnhart, T. E., Betthauser, T. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.006 · Cited by 58
“Increasing evidence suggests that amyloid may be necessary—although even this is contested by some [8]—but not sufficient for developing AD [6,8–11].”
Background
The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype
Pletniková, O., Kageyama, Y., Rudow, G. L., LaClair, K. D., Albert, M., Crain, B. J., Tian, J., Fowler, D. R., & Troncoso, J. C. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.07.007 · Cited by 57
Practical measures to simplify the Braak tangle staging method for routine pathological screening
Harding, A. J., Kril, J. J., & Halliday, G. M. (2000) · Acta Neuropathologica · doi:10.1007/pl00007425 · Cited by 58
“We identified that increasing NFT density in the CA1 is important for differentiating cases with early neuritic pathology and that such pathology can occur in cases without dementia, consistent with many previous studies [3, 12 , 19, 20, 34, 37].”
Result
Influence of functional connectivity and structural MRI measures on episodic memory
He, J., Carmichael, O. T., Fletcher, E. M., Singh, B., Iosif, A., Martinez, O., Reed, B., Yonelinas, A., & DeCarli, C. S. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.029 · Cited by 62
Alzheimer's disease therapeutic research: the path forward
Aisen, P. S. S. (2009) · Alzheimer s Research & Therapy · doi:10.1186/alzrt2 · Cited by 59
“There is a high prevalence of brain amyloid in non-demented elderly individuals at autopsy [21], perhaps an indication of a long pre-symptomatic stage.”
Hypertension and Related Factors in the Etiology of Alzheimer's Disease
Skoog, I. G., & Gustafson, D. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04796.x · Cited by 58
Consensus neuropathological diagnosis of common dementia syndromes: testing and standardising the use of multiple diagnostic criteria
Halliday, G., Ng, T., Rodriguez, M., Harding, A., Blumbergs, P., Evans, W., Fabian, V., Fryer, J., Gonzales, M., Harper, C., et al. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0529-5 · Cited by 57
“As expected in an aged but cognitively normal population [ 6 ], all four control cases had some minor neuropathological changes including small numbers of plaques, tan- 73”
Result
Humanin and the Receptors for Humanin
Matsuoka, M., & Hashimoto, Y. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8090-z · Cited by 56
Is Alzheimer’s disease inevitable with age?
Morris, J. C. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8560 · Cited by 56
“Further investigations with larger numbers of nondemented control subjects revealed that AD may be present neuropathologically but was not associated with clinically detectable cognitive change during life (17, 18).”
Background
Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment—Part 2
Evans, D. A., Grodstein, F., Loewenstein, D., Kaye, J. A., & Weıntraub, S. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.11.008 · Cited by 55
“[5] Davis DG, Schmitt FA, Wekstein DR, Markesbery WR.”
Background
Sex and gonadal hormones in mouse models of Alzheimer’s disease: what is relevant to the human condition?
Dubal, D. B., Broestl, L., & Worden, K. (2012) · Biology of Sex Differences · doi:10.1186/2042-6410-3-24 · Cited by 62
“Highlights from this large body of literature include: cognitive deficits often develop prior to the deposition of amyloid plaques [21-23], neurofibrillary tangles can exist without neuronal impairment [14,16,2427], and tau alone can exert toxicity independently of neurofibrillary tangles (reviewed in [28]).”
Background
Subjective Memory Complaints in APOE ɛ 4 Carriers are Associated with High Amyloid-β Burden
Zwan, M. D., Villemagne, V. L., Doré, V., Buckley, R. F., Bourgeat, P., Veljanoski, R., Salvado, O., Williams, R., Margison, L., Rembach, A., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150446 · Cited by 55
Argyrophilic Grain Disease in Demented Subjects Presenting Initially With Amnestic Mild Cognitive Impairment
Jicha, G. A., Petersen, R. C., Knopman, D. S., Boeve, B. F., Smith, G. E., Geda, Y. E., Johnson, K., Cha, R. H., DeLucia, M. W., Braak, H., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000225312.11858.57 · Cited by 52
Vascular Risk Factors
de la Torre, J. C. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513494457 · Cited by 58
Neuronal and Nonneuronal Quantitative BACE Immunocytochemical Expression in the Entorhinohippocampal and Frontal Regions in Alzheimer’s Disease
Leuba, G., Wernli, G., Vernay, A., Kraftsik, R., Mohajeri, M. H., & Saini, K. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000083496 · Cited by 52
Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype
Bangen, K. J., Initiative, F. T. A. D. N., Clark, A. L., Werhane, M., Edmonds, E. C., Nation, D. A., Evangelista, N., Libon, D. J., Bondi, M. W., & Delano-Wood, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150900 · Cited by 51
“Specifically, our results dovetail with neuropathological studies that have demonstrated that 33–50% of individuals without cognitive impairment show a significant amount of AD pathology at autopsy [38–41], and 10–30% of cognitively normal participants have considerably high brain levels of A (PiB and florbetapir stud…”
White matter inflammation and cognitive function in a co-morbid metabolic syndrome and prodromal Alzheimer’s disease rat model
Ivanova, N., Liu, Q., Agca, C., Ağca, Y., Noble, E. G., Whitehead, S. N., & Cechetto, D. F. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1698-7 · Cited by 51
“This is in line with studies of human brain showing a lack of correlation between amyloid plaque burden and presence or severity of dementia symptoms [50, 51].”
Result
Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer’s disease
Moreno‐Rodríguez, M., Perez, S. E., Nadeem, M., Malek‐Ahmadi, M. H., & Mufson, E. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1723-x · Cited by 53
The therapeutic potential of the endocannabinoid system for Alzheimer's disease
Karl, T., Cheng, D., Garner, B., & Arnold, J. C. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.671812 · Cited by 51
“Furthermore, the brain regions showing high levels of inflammation coincide with regions thought to be responsible for the memory impairments observed in the early stages of AD [18] Interestingly, human studies suggest that there is also a pronounced defect in innate immunity in AD, which impairs Ab phagocytosis [19].”
Background
Argyrophilic grain disease: frequency and neuropathology in centenarians
Ding, Z., Wang, Y., Jiang, Y., Yoshida, M., Mimuro, M., Inagaki, T., Iwase, T., & Hashizume, Y. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0043-2 · Cited by 50
PET imaging of neural activity, β-amyloid, and tau in normal brain aging
Zhang, K., Mizuma, H., Zhang, X., Takahashi, K., Jin, C., Song, F., Gao, Y., Kanayama, Y., Wu, Y., Li, Y., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05230-5 · Cited by 49
Cognitive Reserve Proxies Relate to Gray Matter Loss in Cognitively Healthy Elderly with Abnormal Cerebrospinal Fluid Amyloid-β Levels
Arenaza‐Urquijo, E. M., Molinuevo, J. L., Sala‐Llonch, R., Solé‐Padullés, C., Balasa, M., Bosch, B., Olives, J., Antonell, A., Lladó, A., Sánchez‐Valle, R., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121906 · Cited by 50
“Keywords: Aging, amyloid, cognitive reserve, hippocampus, structural MRI”
Neuroimaging Results Impose New Views on Alzheimer’s Disease—the Role of Amyloid Revised
Fjell, A. M., & Walhovd, K. B. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8228-7 · Cited by 48
“When it comes to results from human studies, there are at least two problems with the face validity of the amyloid hypothesis: First, presence of Aβ-plaques in the brain is not sufficient to cause AD [40–46], and typically about one third of elderly without cognitive or clinical symptoms is found to have plaques witho…”
Background
Fornix white matter glia damage causes hippocampal gray matter damage during age-dependent limbic decline
Metzler‐Baddeley, C., Mole, J. P., Sims, R., Fasano, F., Evans, J., Jones, D. K., Aggleton, J. P., & Baddeley, R. (2019) · Scientific Reports · doi:10.1038/s41598-018-37658-5 · Cited by 50
Tau protein aggregation in the frontal and entorhinal cortices as a function of aging
Yang, W., Ang, L. C., & Strong, M. J. (2005) · Developmental Brain Research · doi:10.1016/j.devbrainres.2005.02.004 · Cited by 48
Resilience of Precuneus Neurotrophic Signaling Pathways Despite Amyloid Pathology in Prodromal Alzheimer’s Disease
Perez, S. E., He, B., Nadeem, M., Wuu, J., Scheff, S. W., Abrahamson, E. E., Ikonomović, M. D., & Mufson, E. J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.016 · Cited by 47
Direct Observation of Single Amyloid-β(1-40) Oligomers on Live Cells: Binding and Growth at Physiological Concentrations
Johnson, R. D., Schauerte, J. A., Wisser, K. C., Gafni, A., & Steel, D. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023970 · Cited by 48
“Levels of various soluble, oligomeric forms of Ab have repeatedly been shown to be a stronger indicator of disease state in humans than plaque load [4,5,21,22].”
Background
Calcium dysregulation in relation to Alzheimer‐type pathology in the ageing brain
Garwood, C., Faizullabhoy, A., Wharton, S. B., Ince, P. G., Heath, P. R., Shaw, P. J., Baxter, L., Gelsthorpe, C., Forster, G., Matthews, F. E., et al. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12033 · Cited by 47
“However, population-based neuropathological studies have found that Alzheimer-type pathology is not unique to clinically defined AD, but may be found in ageing brains from individuals without dementia and there is considerable overlap in burdens of Alzheimer-type pathology between demented and nondemented individuals…”
Neuropsychological Profiles and Trajectories in Preclinical Alzheimer’s Disease
Ho, J. K., Nation, D. A., & Initiative, A. D. N. (2018) · Journal of the International Neuropsychological Society · doi:10.1017/s135561771800022x · Cited by 52
Alzheimer disease and other dementias
Alva, G., & Potkin, S. G. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(03)00028-4 · Cited by 48
Cerebral amyloid angiopathy in traumatic brain injury: association with apolipoprotein E genotype
Leclercq, P. D. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.025528 · Cited by 46
Prediction of Preclinical Alzheimer's Disease: Longitudinal Rates of Change in Cognition
Riley, K. P., Jicha, G. A., Davis, D. G., Abner, E. L., Cooper, G. E., Stiles, N. J., Smith, C. D., Kryscio, R. J., Nelson, P. T., Eldik, L. J. V., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-102133 · Cited by 55
“708 K.P. Riley et al. / Preclinical ments and amyloid-ligand binding PET studies, volumetric MRI and fMRI studies [3, 7, 8, 11–24].”
Self-citation
The Differential Effects of Alzheimer's Disease and Lewy Body Pathology on Cognitive Performance: a Meta-analysis
Gurnani, A. S., & Gavett, B. E. (2016) · Neuropsychology Review · doi:10.1007/s11065-016-9334-0 · Cited by 46
“Three out of the 33 studies (Caramelli et al. 1998; Davis et al. 1999; Johnson et al. 2009) did not include a pathologically normal or DLB comparison group and were excluded from the meta-analysis.”
Result
Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimer’s disease
Kang, S. S., Ahn, E. H., & Ye, K. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00494-7 · Cited by 46
Plasticity in Early Alzheimer Disease
Hill, N. L., Kolanowski, A. M., & Gill, D. J. (2011) · Topics in Geriatric Rehabilitation · doi:10.1097/tgr.0b013e31821e588e · Cited by 51
Comparative neuropathology in aging primates: A perspective
Freire‐Cobo, C., Edler, M. K., Varghese, M., Munger, E. L., Laffey, J., Raia, S., In, S. S., Wicinski, B. A., Medalla, M., Perez, S. E., et al. (2021) · American Journal of Primatology · doi:10.1002/ajp.23299 · Cited by 46
“…entorhinal cortex, CA1, CA2‐3, hilus, and subiculum of nondemented older subjects (Bouras et al., 1994, 2002; Bussière, Giannakopoulos, et al., 2003; Davis et al., 1999; Giannakopoulos et al., 1993, 1995, 1996; Giannakopoulos, Hof, Giannakopoulos, et al., 1994; Giannakopoulos, Hof, et al., 1997;…”
Background
Impaired Glucose Tolerance and Reduced Plasma Insulin Precede Decreased AKT Phosphorylation and GLUT3 Translocation in the Hippocampus of Old 3xTg-AD Mice
Griffith, C. M., Macklin, L. N., Cai, Y., Sharp, A. A., Yan, X., Reagan, L. P., Strader, A. D., Rose, G. M., & Patrylo, P. R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180707 · Cited by 44
“Further, clinical data reveal that subjects can exhibit AD-related neuropathology (plaques and tangles) yet remain cognitively intact and, conversely, that subjects can exhibit AD-related dementia yet have little to no neuropathology [59–64].”
Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity
Yagensky, O., Kohansal-Nodehi, M., Gunaseelan, S., Rabe, T., Zafar, S., Zerr, I., Härtig, W., Urlaub, H., & Chua, J. J. E. (2019) · eLife · doi:10.7554/elife.47498 · Cited by 43
“However, the aggregation of Ab and tau alone does not fully account for the cognitive decline observed in AD patients (Davis et al., 1999).”
Background
Artificial Neural Networks and Artificial Organisms Can Predict Alzheimer Pathology in Individual Patients Only on The Basis of Cognitive and Functional Status
Buscema, M., Grossi, E., Snowdon, D. A., Antuono, P., Intraligi, M., Maurelli, G., & Savarè, R. (2004) · Neuroinformatics · doi:10.1385/ni:2:4:399 · Cited by 42
The association of MIND diet with cognitive resilience to neuropathologies
Wagner, M., Agarwal, P., Leurgans, S. E., Bennett, D. A. A., Schneider, J. A., Capuano, A. W., & Grodstein, F. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12982 · Cited by 45
“Co-morbidities, median (IQR) 2 (1;2) 2 (1;3) 2 (1;2) 2 (1;3)”
Early Alzheimer-type lesions in cognitively normal subjects
Tsartsalis, S., Xekardaki, A., Hof, P. R., Kövari, E., & Bouras, C. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.10.002 · Cited by 41
An Update on the Amyloid Hypothesis
Eckman, C. B., & Eckman, E. A. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.007 · Cited by 43
“For example, in a study by Markesbery’s group, significant AD-like pathology (plaques and tangles) was found in the brains of a substantial number of elderly, cognitively normal individuals [55].”
Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-β–negative cognitively normal individuals
Groot, C., Doré, V., Robertson, J. S., Burnham, S. C., Savage, G. R., Ossenkoppele, R., Rowe, C. C., & Villemagne, V. L. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.09.017 · Cited by 41
Cognitive aging and Alzheimer’s disease
Vandenberghe, R. R., & Tournoy, J. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.028290 · Cited by 45
Serum Lipids Are Related to Alzheimer’s Pathology in Nursing Home Residents
Lesser, G. T., Haroutunian, V. H., Purohit, D. P., Beeri, M. S., Schmeidler, J., Honkanen, L., Neufeld, R. R., & Libow, L. S. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000189268 · Cited by 41
Argyrophilic grain disease
Tolnay, M., & Probst, A. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01251-1 · Cited by 41
Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA)
Brown, A. M., Sheu, R. K.-F., Mohs, R., Haroutunian, V., & Blass, J. P. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:16:1:41 · Cited by 40
Alzheimer Lesions in the Autopsied Brains of People 30 to 50 Years of Age
Pletniková, O., Rudow, G. L., Hyde, T. M., Kleinman, J. E., Ali, S. Z., Bharadwaj, R. A., Gangadeen, S., Crain, B. J., Fowler, D. R., Rubio, A. I., et al. (2015) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000071 · Cited by 40
“…of asymptomatic AD emerged from autopsies, first in cross-sectional and then in longitudinal studies (Bennett et al, 2006; Crystal et al, 1988; Davis et al, 1999; Dickson et al, 1992; Miller et al, 1984; Morris and Price, 2001; Morris et al, 2001; Price et al, 2009; Sparks et al, 1993;…”
Background
Glucose/mitochondria in neurological conditions
Blass, J. P. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)51010-2 · Cited by 40
Lack of association between mtDNA haplogroups and Alzheimer’s disease in Tuscany
Mancuso, M., Nardini, M., Micheli, D., Rocchi, A., Nesti, C., Giglioli, N. J., Petrozzi, L., Rossi, C. A., Ceravolo, R., Bacci, A., et al. (2007) · Neurological Sciences · doi:10.1007/s10072-007-0807-z · Cited by 40
“However, although this cascade is potentially viable in familial AD cases with mutation in APP and PS genes, its role in the majority of SAD cases without mutations in these genes is unclear; further, plaques are a relatively common finding in the non-demented elderly [2].”
Background
Judgment of Emotional Nonlinguistic Vocalizations: Age-Related Differences
Fecteau, S., Armony, J. L., Joanette, Y., & Belin, P. (2005) · Applied Neuropsychology · doi:10.1207/s15324826an1201_7 · Cited by 45
Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases
Yoshida, K., Hata, Y., Ichimata, S., Okada, K., & Nishida, N. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00352-2 · Cited by 38
“identified AGD in 23% of 59 cognitively normal older adult subjects [16], and Knopman et al.”
BackgroundResult
Ultrastructure evidence of necrotic neural cell death in familial Alzheimer's disease brains bearing presenilin-1 E280A mutation1
Velez‐Pardo, C., Tobón‐Arroyave, S. I., Lopera, F. J., Castaño, A. D., & Jiménez-Del-Río, M. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3408 · Cited by 38
Small hippocampal size in cognitively normal subjects with coronary artery disease
Koschack, J., & Irle, E. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.009 · Cited by 38
Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study
Varamini, B., Sikalidis, A. K., & Bradford, K. L. (2013) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2013.832171 · Cited by 38
“In humans, a number of studies show that progressive neurodegeneration may occur in AD patients despite removal of plaques, and many cognitively normal humans display Ab plaques in equivalent densities as Alzheimer’s diseased individuals (Davis et al., 1999; Holmes et al., 2008).”
Background
Cerebral Blood Flow Measurement by PET in Hypertensive Subjects as a Marker of Cognitive Decline
Kitagawa, K. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091324 · Cited by 37
“Additionally, the deposition of amyloid-β is also frequently seen in the brain of cognitively normal, aged subjects [6].”
Problems Associated with Biological Markers of Alzheimer’s Disease
Frey, H. J., Mattila, K. M., Korolainen, M. A., & Pirttilä, T. (2005) · Neurochemical Research · doi:10.1007/s11064-005-8827-7 · Cited by 37
“The latter may be due to the frequent existence of AD-type pathology in cognitively healthy subjects and other dementias (17,18).”
Background
Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease
Żukowska, J., Moss, S. J., Subramanian, V., & Acharya, K. R. (2023) · FEBS Journal · doi:10.1111/febs.16939 · Cited by 36
“Perhaps the most signiﬁcant of these is the lack of AD associated cognitive decline in many elderly people that possess large quantities of A b plaques [23,24].”
Three Postulates to Help Identify the Cause of Alzheimer's Disease
de la Torre, J. C. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101884 · Cited by 39
“Multiple studies have failed to show significant correlations between A plaque density in brain and degree of neuronal degeneration or of cognitive failure in AD [12–16].”
Losartan improves cerebrovascular function in a mouse model of Alzheimer's disease with combined overproduction of amyloid-β and transforming growth factor-β1
Papadopoulos, P., Tong, X., Imboden, H., & Hamel, É. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16658489 · Cited by 35
“Additionally, studies showing cognitively unaffected elderly individuals having equivalent Ab plaque densities than AD patients further support the notion that Ab plaques are not good correlates of dementia.(65) Further studies would be needed to decipher any potential role of AT1R antagonists like losartan on hyperph…”
Result
Time for a Systems Biological Approach to Cognitive Aging?—A Critical Review
Ebaid, D., & Crewther, S. G. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00114 · Cited by 43
“This notion stems from the observation of individuals who were functioning below levels of clinical impairment, despite brain pathology that other individuals who demonstrated clinical impairments also showed (Davis et al., 1999; Riley et al., 2002).”
Background
Environmental and Cognitive Enrichment in Childhood as Protective Factors in the Adult and Aging Brain
Schoentgen, B., Gagliardi, G. P., & Defontaines, B. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.01814 · Cited by 44
An Alzheimer's disease hypothesis based on transcriptional dysregulation
Robakis, N. K. R. K. (2003) · Amyloid · doi:10.3109/13506120309041729 · Cited by 33
Neuropathological Changes in Aging Brain
Xekardaki, A., Kövari, E., Gold, G., Papadimitropoulou, A., Giacobini, E., Herrmann, F. R., Giannakopoulos, P., & Bouras, C. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-08939-3_6 · Cited by 35
“Since then several other studies have indicated the presence of NFTs in normal brain aging [28–31].”
Cholesterol and LDL Relate to Neuritic Plaques and to APOE4 Presence but Not to Neurofibrillary Tangles
Lesser, G. T., Beeri, M. S., Schmeidler, J., Purohit, D. P., & Haroutunian, V. (2011) · Current Alzheimer Research · doi:10.2174/156720511795563755 · Cited by 37
Functional connectivity along the anterior–posterior axis of hippocampal subfields in the ageing human brain
Dalton, M. A., McCormick, C., Luca, F. D., Clark, I. A., & Maguire, E. A. (2019) · Hippocampus · doi:10.1002/hipo.23097 · Cited by 32
Are Aβ and Its Derivatives Causative Agents or Innocent Bystanders in AD?
Robakis, N. K. (2010) · Neurodegenerative Diseases · doi:10.1159/000266476 · Cited by 32
Why therapies for Alzheimer’s disease do not work: Do we have consensus over the path to follow?
Amtul, Z. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.09.003 · Cited by 35
Periodontitis and systemic markers of neurodegeneration: A case–control study
Leira, Y., Carballo, Á., Orlandi, M., Aldrey, J. M., Peleteiro, J. M. P., Moreno, F., Vázquez‐Vázquez, L., Campos, F., D’Aiuto, F., Castillo, J., et al. (2020) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13267 · Cited by 33
A novel pectin from Polygala tenuifolia blocks Aβ42 aggregation and production by enhancing insulin-degradation enzyme and neprilysin
Zeng, H., Li, P., Zhou, L., & Ding, K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.05.212 · Cited by 32
Genomics and CSF analyses implicate thyroid hormone in hippocampal sclerosis of aging
Initiative, A. D. N., Nelson, P. T., Katsumata, Y., Nho, K. T., Artiushin, S., Jicha, G. A., Wang, W., Abner, E. L., Saykin, A. J., Kukull, W. A., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1641-2 · Cited by 31
“Pathological assessment methodology at the UK-ADC has been described in detail [18, 62, 78, 98].”
Functional Changes in the Language Network in Response to Increased Amyloid β Deposition in Cognitively Intact Older Adults
Adamczuk, K., Weer, A. D., Nelissen, N., Dupont, P. J., Sunaert, S. G., Bettens, K., Sleegers, K., Broeckhoven, C. V., Laere, K. V., & Vandenberghe, R. R. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhu286 · Cited by 32
“…manifestations of underlying Alzheimer pathology and who remain cognitively intact despite the presence of Alzheimer pathology in the brain (Crystal et al. 1988; Katzman et al. 1988; Troncoso et al. 1996; Davis et al. 1999; Price and Morris 1999; Driscoll et al. 2006; Aizenstein et al. 2008).”
Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer’s disease
Lovell, M. A., Robertson, J. D., Buchholz, B. A., Xie, C., & Markesbery, W. R. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00281-0 · Cited by 29
Self-citation
Innate immunity in Alzheimer’s disease: the relevance of animal models?
Franco-Bocanegra, D., Nicoll, J. A. R., & Boche, D. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1729-4 · Cited by 32
“2008), corroborating the previous studies that pointed out the lack of association between amyloid pathology and severity of dementia (Davis et al. 1999; CFAS 2001; Engler et al. 2006; Minett et al. 2016).”
Result
Spatiotemporal activation of the C/EBPβ/δ-secretase axis regulates the pathogenesis of Alzheimer’s disease
Wang, H., Liu, X., Chen, S., & Ye, K. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815915115 · Cited by 32
“For example, many cognitively normal elderly individuals display relatively large amounts of Aβ in their brains (32, 33).”
Background
Structural evolution and membrane interactions of Alzheimer's amyloid‐beta peptide oligomers: New knowledge from single‐molecule fluorescence studies
Johnson, R. D., Steel, D. G., & Gafni, A. (2014) · Protein Science · doi:10.1002/pro.2479 · Cited by 29
T2 heterogeneity: a novel marker of microstructural integrity associated with cognitive decline in people with mild cognitive impairment
Wearn, A. R., Nurdal, V., Saunders-Jennings, E., Knight, M. J., Isotalus, H., Dillon, S., Tsivos, D., Kauppinen, R. A., & Coulthard, E. J. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00672-9 · Cited by 27
Cholesterol and Synaptic Compensatory Mechanisms in Alzheimer's Disease Mice Brain During Aging
Jansen, D., Janssen, C. I. F., Vanmierlo, T., Dederen, P. J. W. C., van Rooij, D., Zinnhardt, B., Nobelen, C. L. M., Janssen, A.-L., Hafkemeijer, A., Mutsaers, M. P. C., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120298 · Cited by 29
“Many non-demented individuals show large amounts of AD pathology, whereas many AD patients display only few A depositions, as shown in large autopsy studies [5, 6], and in PET [11C] Pittsburgh Compound-B imaging studies visualizing A plaque burden in vivo [7, 8].”
Inflammation and aging: Can endocannabinoids help?
Marchalant, Y., Brothers, H. M., & Wenk, G. L. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.02.004 · Cited by 27
“Moreover, the development of inflammation within neuronal populations and regions known to be vulnerable in the brains of AD coincide with the memory impairments observed in the early stages of AD pathology (Davis et al., 1999).”
Background
Consideration of the ischaemic basis and treatment of Alzheimer's disease.
Pluta, R. M., Ułamek, M., & Jabłoński, M. (2010) · PubMed · Cited by 29
Mild Cognitive Impairment: Where Are We?
Petersen, R. C. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000179417.95584.90 · Cited by 29
THE NOSOLOGY OF DEMENTIA
Morris, J. C. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70225-5 · Cited by 29
White Matter Changes in Bipolar Disorder, Alzheimer Disease, and Mild Cognitive Impairment: New Insights from DTI
Xekardaki, A., Giannakopoulos, P., & Haller, S. (2011) · Journal of Aging Research · doi:10.4061/2011/286564 · Cited by 28
“FA, MD, RD, and LD were measured using TBSS. FA was significantly higher in controls compared to MCI in a network involving the corpus callosum, right temporal and frontal pathways.”
Method
Beer Drinking Associates with Lower Burden of Amyloid Beta Aggregation in the Brain: Helsinki Sudden Death Series
Kok, E., Karppinen, T. T., Luoto, T. M., Alafuzoff, I. I., & Karhunen, P. J. (2016) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13102 · Cited by 27
Early Stage Alterations in CA1 Extracellular Region Proteins Indicate Dysregulation of IL6 and Iron Homeostasis in the 5XFAD Alzheimer’s Disease Mouse Model
Gürel, B., Cansev, M., Koç, C., Keleştemur, S., Öcalan, B., Çakır, A., Aydın, S., Kahveci, N., Ozansoy, M., Taşkapılıoğlu, Ö., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170329 · Cited by 28
“Although this is a highly accepted theory, there are many healthy subjects with brains containing abundant neuroﬁbrillary tangle and senile plaques without any cognitive decline [58].”
Comparison of Amyloid β and Tau Spread Models in Alzheimer’s Disease
Kim, H., Lee, P., Seo, S. W., Roh, J. H., Oh, M., Oh, J. S., Oh, S. J., Kim, J. S., & Jeong, Y. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy311 · Cited by 32
“2015), has been repeatedly demonstrated in both neuropathological (Davis et al. 1999; Bennett et al. 2006; Braak et al. 2011) and PET studies (Schöll et al.”
Background
Metabotropic glutamate receptor 5 ablation accelerates age-related neurodegeneration and neuroinflammation
Carvalho, T. G., Alves‐Silva, J., de Souza, J. M., Real, A. L. C. V., Doria, J. G., Vieira, É. L. M., Gomes, G. F., de Oliveira, A. C., de Miranda, A. S., & Ribeiro, F. M. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.03.020 · Cited by 28
“abnormalities in microglial population (Davis et al., 1999; Streit et al., 2004).”
Synergistic Interactions between Alzheimer’s Aβ40 and Aβ42 on the Surface of Primary Neurons Revealed by Single Molecule Microscopy
Chang, C.-C., Althaus, J. C., Carruthers, C. J. L., Sutton, M. A., Steel, D. G., & Gafni, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082139 · Cited by 28
Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer’s Disease
Edmonds, E. C., Bangen, K. J., Delano‐Wood, L., Nation, D. A., Furst, A. J., Salmon, D. P., Bondi, M. W., & Initiative, A. D. N. (2016) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617716000928 · Cited by 28
Detergent Insoluble Proteins and Inclusion Body-Like Structures Immunoreactive for PRKDC/DNA-PK/DNA-PKcs, FTL, NNT, and AIFM1 in the Amygdala of Cognitively Impaired Elderly Persons
Gál, J., Chen, J., Katsumata, Y., Fardo, D. W., Wang, W., Artiushin, S., PRICE, D. A., Anderson, S., Patel, E., Zhu, H., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx097 · Cited by 28
Risk for Alzheimer's disease in older late-onset cases is associated with HLA-DRB1*03
Neill, D., Curran, M. D., Middleton, D., Mawhinney, H., Edwardson, J. A., McKeith, I. G., Ballard, C. G., Morris, C. M., Ince, P. G., Jaros, E., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00761-2 · Cited by 28

Authors: Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. R.
Affiliations: University of Kentucky HealthCare (US)
Corresponding author: Davis, D G
ORCID: Schmitt, F A
Venue: Journal of Neuropathology and Experimental Neurology
Publisher: Oxford University Press (OUP)
Published: 1999-04
Volume: 58
Issue: 4
Pages: 376-388
ISSN: 0022-3069 (ISSN-L)
DOI: 10.1097/00005072-199904000-00008
OpenAlex: W2009882167
Cited by: 516
References: 0
Citations by year: 2026: 2 · 2025: 6 · 2024: 6 · 2023: 12 · 2022: 7 · 2021: 13 · 2020: 14 · 2019: 16 · 2018: 22 · 2017: 16 · 2016: 26 · 2015: 18 · 2014: 30 · 2013: 25 · 2012: 19
FWCI: 15.68
Type: journal article
Language: en
Open access: closed
Locations: Journal of Neuropathology & Experimental Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Aging (P50AG005144, P50-AGO5144, 1PO1-AGO51195)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords: Alzheimer's disease, normal aging, amyloid plaques, neurofibrillary tangles, Braak staging, dementia with Lewy bodies, cerebral amyloid angiopathy, entorhinal cortex, hippocampus, amygdala, neuropathology
MeSH terms: Aged, Aged, 80 and over, Aging, Alzheimer Disease, Amyloidosis, Apolipoproteins E, Brain, Cerebral Infarction, Chronic Disease, Cognition, Female, Genotype, Craniocerebral Trauma, Humans, Male, Mental Status Schedule, Middle Aged, Dementia, Vascular, Silver Staining, Lewy Bodies, Neurofibrillary Tangles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alzheimer Neuropathologic Alterations in Aged Cognitively Normal Subjects

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks